PMID- 35709642
OWN - NLM
STAT- MEDLINE
DCOM- 20220804
LR  - 20220821
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 439
DP  - 2022 Aug 15
TI  - Clinical implication of denervation in sporadic inclusion body myositis.
PG  - 120317
LID - S0022-510X(22)00179-4 [pii]
LID - 10.1016/j.jns.2022.120317 [doi]
AB  - INTRODUCTION: Sporadic inclusion body myositis (sIBM) is often accompanied by 
      signs suggestive of denervation on electromyography (EMG), which mimics 
      neurogenic disorders. Hence, the current study aimed to assess reinnervation 
      after denervation in sIBM and its clinical impllcation. METHODS: We 
      retrospectively examined consecutive muscle biopsy specimens collected from 109 
      sIBM patients who were referred to our institution for diagnostic muscle biopsy 
      from 2001 to 2018. Reinnervation after denervation in sIBM patients was assessed 
      via muscle biopsy and EMG. The levels of acetylcholine receptor subunit gamma (Chrng) 
      and muscle-specific kinase (MuSK) mRNA, which are markers of denervation, were 
      examined using real-time polymerase chain reaction. Response to treatment was 
      defined as an increase of grade 1 or higher in two or more muscle groups as 
      assessed using the Medical Research Council scale. RESULTS: In total, 93 (85.3%) 
      of 109 sIBM patients had reinnervation after denervation on histological 
      examination and/or EMG. The mean disease duration before biopsy was significantly 
      longer in patients with reinnervation after denervation than in those without 
      (p < 0.00001). Patients with denervation had significantly higher levels of Chrng 
      and MuSK mRNA than those without. The proportion of patients who responded to 
      immunosuppressive therapies was smaller in the patients with denervation than 
      those without (p < 0.05). However, there was no significant difference regarding 
      time from onset to using a walking aid between the two groups. DISCUSSION: 
      Reinnervation after denervation is associated with disease duration and 
      short-term response to therapy in individuals with sIBM.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Noda, Seiya
AU  - Noda S
AD  - Department of Neurology, Nagoya University Graduate School of Medicine, Japan; 
      Department of Neurology, National Hospital Organization Suzuka Hospital, Japan.
FAU - Murakami, Ayuka
AU  - Murakami A
AD  - Department of Neurology, Nagoya University Graduate School of Medicine, Japan; 
      Department of Neurology, National Hospital Organization Suzuka Hospital, Japan.
FAU - Kazuta, Tomoyuki
AU  - Kazuta T
AD  - Department of Neurology, Nagoya University Graduate School of Medicine, Japan; 
      Department of Neurology, National Hospital Organization Suzuka Hospital, Japan.
FAU - Hirano, Satoko
AU  - Hirano S
AD  - Department of Neurology, Nagoya University Graduate School of Medicine, Japan; 
      Department of Neurology, National Hospital Organization Suzuka Hospital, Japan.
FAU - Kimura, Seigo
AU  - Kimura S
AD  - Department of Neurology, Nagoya University Graduate School of Medicine, Japan; 
      Department of Neurology, National Hospital Organization Suzuka Hospital, Japan.
FAU - Nakanishi, Hirotaka
AU  - Nakanishi H
AD  - Department of Neurology, Yokkaichi Municipal Hospital, Japan.
FAU - Matsuo, Koji
AU  - Matsuo K
AD  - Department of Neurology, Kariya Toyota General Hospital, Japan.
FAU - Tsujikawa, Koyo
AU  - Tsujikawa K
AD  - Department of Neurology, Nagoya University Graduate School of Medicine, Japan.
FAU - Yamada, Shinichiro
AU  - Yamada S
AD  - Department of Neurology, Nagoya University Graduate School of Medicine, Japan.
FAU - Iida, Madoka
AU  - Iida M
AD  - Department of Neurology, Nagoya University Graduate School of Medicine, Japan.
FAU - Koike, Haruki
AU  - Koike H
AD  - Department of Neurology, Nagoya University Graduate School of Medicine, Japan.
FAU - Kuru, Satoshi
AU  - Kuru S
AD  - Department of Neurology, National Hospital Organization Suzuka Hospital, Japan.
FAU - Katsuno, Masahisa
AU  - Katsuno M
AD  - Department of Neurology, Nagoya University Graduate School of Medicine, Japan; 
      Department of Clinical Research Education, Nagoya University Graduate School of 
      Medicine, Japan. Electronic address: ka2no@med.nagoya-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220608
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Denervation
MH  - Electromyography
MH  - Humans
MH  - *Myositis, Inclusion Body/diagnosis
MH  - RNA, Messenger
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Denervation
OT  - Muscle biopsy
OT  - Prognosis
OT  - Sporadic inclusion body myositis
EDAT- 2022/06/17 06:00
MHDA- 2022/08/05 06:00
CRDT- 2022/06/16 18:22
PHST- 2022/03/07 00:00 [received]
PHST- 2022/05/08 00:00 [revised]
PHST- 2022/06/03 00:00 [accepted]
PHST- 2022/06/17 06:00 [pubmed]
PHST- 2022/08/05 06:00 [medline]
PHST- 2022/06/16 18:22 [entrez]
AID - S0022-510X(22)00179-4 [pii]
AID - 10.1016/j.jns.2022.120317 [doi]
PST - ppublish
SO  - J Neurol Sci. 2022 Aug 15;439:120317. doi: 10.1016/j.jns.2022.120317. Epub 2022 
      Jun 8.